The MetNET-2 Trial
This is a Pilot, One-arm, Open-label, Prospective Study to evaluate Safety of Lanreotide 120
mg ATG in combination with Metformin in patients with advanced progressive GI or lung
The patient population will include patients with a histologically documented diagnosis of
Well differentiated NET, G1-G2 according to the last WHO Classification criteria for GI and
lung NET carcinoids.